Pharmadrug Inc.
PHRX
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -95.02% | -63.91% | 47.44% | 30.11% | 22.22% |
| Depreciation & Amortization | 26.57% | 90.16% | 7,933.33% | 6,400.00% | 253.09% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -88.62% | -57.05% | 37.30% | 12.24% | 8.48% |
| Operating Income | 88.62% | 57.05% | -37.30% | -12.24% | -8.48% |
| Income Before Tax | 96.99% | 93.86% | -1,065.21% | -1,044.04% | -723.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 96.76% | 93.40% | -894.24% | -1,153.74% | -758.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -11.21% | 100.00% | -- | -- | -- |
| Net Income | 97.43% | 94.29% | -1,034.00% | -660.66% | -91.84% |
| EBIT | 88.62% | 57.05% | -37.30% | -12.24% | -8.48% |
| EBITDA | 91.53% | 60.25% | -32.25% | -9.57% | -7.61% |
| EPS Basic | 98.25% | 95.81% | -697.53% | -435.63% | -33.24% |
| Normalized Basic EPS | 86.51% | 72.09% | -24.29% | -27.85% | 0.00% |
| EPS Diluted | 98.25% | 95.83% | -733.55% | -451.25% | -34.15% |
| Normalized Diluted EPS | 86.51% | 72.09% | -24.29% | -27.85% | 0.00% |
| Average Basic Shares Outstanding | 53.89% | 78.24% | 84.18% | 57.94% | 34.11% |
| Average Diluted Shares Outstanding | 53.89% | 78.24% | 84.18% | 57.94% | 34.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |